Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Windlas Biotech
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 141 | 145 | 153 | 162 | 171 | 175 | 187 | 195 | 203 | 210 | 222 | 233 | 238 |
| Expenses + | 124 | 128 | 134 | 142 | 149 | 154 | 164 | 170 | 177 | 184 | 194 | 209 | 213 |
| Operating Profit | 16 | 17 | 19 | 20 | 22 | 21 | 23 | 25 | 26 | 27 | 29 | 24 | 25 |
| OPM % | 12% | 12% | 12% | 13% | 13% | 12% | 12% | 13% | 13% | 13% | 13% | 10% | 11% |
| Other Income + | 2 | 3 | 3 | 3 | 4 | 4 | 5 | 4 | 5 | 5 | 4 | 5 | 4 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 4 | 3 | 3 | 3 | 4 | 6 | 6 | 7 | 8 | 7 | 8 | 8 | 8 |
| Profit before tax | 15 | 16 | 18 | 20 | 23 | 18 | 20 | 20 | 21 | 23 | 24 | 20 | 20 |
| Tax % | 24% | 26% | 23% | 24% | 25% | 26% | 23% | 23% | 22% | 24% | 25% | 25% | 21% |
| Net Profit + | 11 | 12 | 14 | 15 | 17 | 13 | 16 | 16 | 16 | 18 | 18 | 15 | 16 |
| EPS in Rs | 5.38 | 5.80 | 6.75 | 7.26 | 8.17 | 6.45 | 7.49 | 7.45 | 7.77 | 8.43 | 8.45 | 7.12 | 7.58 |
Financials of Windlas Biotech
Annual income statement trend
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 352 | 307 | 329 | 428 | 466 | 513 | 631 | 760 | 904 |
| Expenses + | 313 | 270 | 295 | 373 | 414 | 453 | 553 | 666 | 799 |
| Operating Profit | 39 | 38 | 34 | 55 | 52 | 60 | 78 | 94 | 105 |
| OPM % | 11% | 12% | 10% | 13% | 11% | 12% | 12% | 12% | 12% |
| Other Income + | 4 | 54 | 2 | -19 | 7 | 10 | 13 | 18 | 18 |
| Interest | 6 | 5 | 3 | 1 | 1 | 1 | 1 | 4 | 5 |
| Depreciation | 17 | 11 | 9 | 13 | 12 | 12 | 13 | 28 | 31 |
| Profit before tax | 20 | 76 | 25 | 22 | 46 | 57 | 77 | 80 | 87 |
| Tax % | 44% | 16% | 34% | 28% | 16% | 25% | 25% | 24% | 24% |
| Net Profit + | 11 | 64 | 16 | 16 | 38 | 43 | 58 | 61 | 66 |
| EPS in Rs | 20.04 | 99.55 | 25.28 | 24.69 | 17.48 | 20.04 | 27.98 | 29.10 | 31.49 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 20% | 20% | 20% | 20% | 20% |
Financials of Windlas Biotech
Capital structure and asset base
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 11 | 10 | 10 | 10 | 11 |
| Reserves | 119 | 187 | 203 | 193 | 384 | 392 | 440 | 495 | 570 |
| Borrowings + | 57 | 32 | 29 | 32 | 7 | 5 | 4 | 33 | 35 |
| Other Liabilities + | 107 | 73 | 100 | 65 | 90 | 122 | 173 | 222 | 291 |
| Total Liabilities | 290 | 298 | 338 | 296 | 491 | 529 | 626 | 760 | 907 |
| Fixed Assets + | 86 | 64 | 70 | 96 | 91 | 109 | 179 | 223 | 217 |
| CWIP | 53 | 5 | 0 | 0 | 8 | 15 | 6 | 5 | 56 |
| Investments | 23 | 122 | 116 | 23 | 65 | 107 | 173 | 223 | 268 |
| Other Assets + | 128 | 107 | 152 | 177 | 327 | 298 | 268 | 308 | 366 |
| Total Assets | 290 | 298 | 338 | 296 | 491 | 529 | 626 | 760 | 907 |
Financials of Windlas Biotech
Operating, investing and financing cash movement
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 35 | 19 | 25 | 11 | 9 | 61 | 109 | 68 | 105 |
| Cash from Investing Activity + | -11 | -7 | -14 | -20 | -155 | -14 | -92 | -74 | -92 |
| Cash from Financing Activity + | -26 | -6 | -5 | 1 | 130 | -44 | -15 | 1 | -13 |
| Net Cash Flow | -2 | 6 | 5 | -8 | -15 | 3 | 2 | -5 | 0 |
| Free Cash Flow | 10 | 10 | 10 | 6 | -6 | -9 | 71 | 16 | 37 |
| CFO/OP | 102% | 81% | 113% | 33% | 34% | 117% | 163% | 95% | 115% |
Financials of Windlas Biotech
Working capital efficiency and return ratios
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 69 | 73 | 71 | 68 | 87 | 83 | 79 | 80 | 92 |
| Inventory Days | 54 | 36 | 85 | 55 | 71 | 84 | 57 | 63 | 40 |
| Days Payable | 130 | 110 | 143 | 53 | 76 | 98 | 121 | 129 | 156 |
| Cash Conversion Cycle | -7 | -1 | 13 | 70 | 81 | 69 | 15 | 14 | -24 |
| Working Capital Days | -30 | -12 | 2 | 40 | 85 | 71 | 32 | 17 | 123 |
| ROCE % | 15% | 12% | 19% | 15% | 14% | 18% | 17% | 16% |
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…